Evidence map›Paper›PMID 26698860›Full record

Observational studyPloS one2015

Parkinson Symptoms and Health Related Quality of Life as Predictors of Costs: A Longitudinal Observational Study with Linear Mixed Model Analysis.

Pablo Martinez-Martín, Carmen Rodriguez-Blazquez, Silvia Paz, Maria João Forjaz, Belén Frades-Payo, Esther Cubo, Jesús de Pedro-Cuesta, Luis Lizán, ELEP Group

Abstract readMulticenter StudyObservational Study
In one paragraph

Observational study in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Understanding the Potential of Genome Editing in Parkinson's Disease.International journal of molecular sciences · 2021
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Pablo Martinez-MartínNational Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain.
Carmen Rodriguez-BlazquezNational Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain.
Silvia PazOutcomes' 10, Jaume I University, Castellon de la Plana, Castellon, Spain.
Maria João ForjazNational School of Public Health and REDISSEC, Carlos III Institute of Health, Madrid, Spain.
Belén Frades-PayoResearch Unit, Alzheimer Center Reina Sofia Foundation, Carlos III Institute of Health, Madrid, Spain.
Esther CuboComplejo Asistencial Universitario de Burgos, Burgos, Spain.
Jesús de Pedro-CuestaNational Center of Epidemiology and CIBERNED, Carlos III Institute of Health, Madrid, Spain.
Luis LizánOutcomes' 10, Jaume I University, Castellon de la Plana, Castellon, Spain.
ELEP Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo estimate the magnitude in which Parkinson's disease (PD) symptoms and health- related quality of life (HRQoL) determined PD costs over a 4-year period. MATERIALS AND

methodsData collected during 3-month, each year, for 4 years, from the ELEP study, included sociodemographic, clinical and use of resources information. Costs were calculated yearly, as mean 3-month costs/patient and updated to Spanish €, 2012. Mixed linear models were performed to analyze total, direct and indirect costs based on symptoms and HRQoL.

resultsOne-hundred and seventy four patients were included. Mean (SD) age: 63 (11) years, mean (SD) disease duration: 8 (6) years. Ninety-three percent were HY I, II or III (mild or moderate disease). Forty-nine percent remained in the same stage during the study period. Clinical evaluation and HRQoL scales showed relatively slight changes over time, demonstrating a stable group overall. Mean (SD) PD total costs augmented 92.5%, from € 2,082.17 (€ 2,889.86) in year 1 to € 4,008.6 (€ 7,757.35) in year 4. Total, direct and indirect cost incremented 45.96%, 35.63%, and 69.69% for mild disease, respectively, whereas increased 166.52% for total, 55.68% for direct and 347.85% for indirect cost in patients with moderate PD. For severe patients, cost remained almost the same throughout the study. For each additional point in the SCOPA-Motor scale total costs increased € 75.72 (p = 0.0174); for each additional point on SCOPA-Motor and the SCOPA-COG, direct costs incremented € 49.21 (p = 0.0094) and € 44.81 (p = 0.0404), respectively; and for each extra point on the pain scale, indirect costs increased € 16.31 (p = 0.0228).

conclusionsPD is an expensive disease in Spain. Disease progression and severity as well as motor and cognitive dysfunctions are major drivers of costs increments. Therapeutic measures aimed at controlling progression and symptoms could help contain disease expenses.

Indexed as

Health Care CostsLinear ModelsQuality of LifeCross-Sectional StudiesFemaleHumansLongitudinal StudiesMaleMiddle AgedParkinson DiseaseParkinson Disease, SecondaryPrognosis

Identifiers

PMID26698860
PMCPMC4689528

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.